רווח למניה בשנים עשר החודשים האחרונים: Champions Oncology Inc (CSBR)

The business resilience of Champions Oncology (CSBR) driven by unique data and certifications minimizes financial risks, as evidenced by the company's annual net profit per share. The -0.08 mark serves as the key metric on this chart. Capital optimization relies on stable R&D funding and expanding demand from biotech behemoths for high-precision drug testing platforms, ensuring sustainable growth in performance indicators.
פילוחים אנליטיים של חברת Champions Oncology Corp (CSBR)

For Champions Oncology (CSBR), this indicator reflects the effectiveness of monetizing demand for high-precision preclinical oncology research. Trailing twelve-month (TTM) net income per share is calculated by dividing the bottom-line financial result by the total number of shares. This metric offsets the impact of equity dilution, allowing for an assessment of the real income per share. An analysis of the TTM net income per share trend reveals business resilience during client base expansion. The chart's extremes serve as a signal to revise the investment valuation of the asset.